Table 1.
Associations between AGGF1 expression and clinicopathological characteristics in 236 CRC patients
| Variable | n | AGGF1 expression | p value | ||
|---|---|---|---|---|---|
| Negative (46) | Weak positive (76) | Strong positive (114) | |||
| Age (yr) | 0.837 | ||||
| < 57 | 112 | 22 (19.6%) | 34 (30.4%) | 56 (50.0%) | |
| > =57 | 124 | 24 (19.4%) | 42 (33.9%) | 58 (46.8%) | |
| Gender | 0.359 | ||||
| Male | 139 | 23 (16.5%) | 45 (32.4%) | 71 (51.1%) | |
| Female | 97 | 23 (23.7%) | 31 (32.0%) | 43 (44.3%) | |
| Tumor location | 0.381 | ||||
| Right | 49 | 5 (10.2%) | 15 (30.6%) | 29 (59.2%) | |
| Transverse | 5 | 1 (20.0%) | 2 (40.0%) | 2 (40.0%) | |
| Left | 12 | 2 (16.7%) | 3 (25.0%) | 7 (58.3%) | |
| Sigmoid | 49 | 7 (14.3%) | 16 (32.7%) | 26 (53.1%) | |
| Rectum | 121 | 31 (25.6%) | 40 (33.1%) | 50 (41.3%) | |
| T classification | < 0.001* | ||||
| T 1 | 2 | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | |
| T 2 | 36 | 21 (58.3%) | 7 (19.4%) | 8 (22.2%) | |
| T 3 | 44 | 7 (15.9%) | 21 (47.7%) | 16 (36.4%) | |
| T 4 | 154 | 16 (10.4%) | 48 (31.2%) | 90 (58.4%) | |
| N classification | < 0.001* | ||||
| N 0 | 108 | 36 (33.3%) | 44 (40.7%) | 28 (25.9%) | |
| N 1 | 77 | 7 (9.1%) | 18 (23.4%) | 52 (67.5%) | |
| N 2 | 51 | 3 (5.9%) | 14 (27.5%) | 34 (66.7%) | |
| M classification | 0.012* | ||||
| M 0 | 204 | 44 (21.6%) | 69 (33.8%) | 91 (44.6%) | |
| M 1 | 32 | 2 (6.3%) | 7 (21.9%) | 23 (71.9%) | |
| AJCC stage | < 0.001* | ||||
| I | 24 | 19 (79.2%) | 5 (20.8%) | 0 (0.0%) | |
| II | 76 | 15 (19.7%) | 36 (47.4%) | 25 (32.9%) | |
| III | 104 | 10 (9.6%) | 28 (26.9%) | 66 (63.5%) | |
| IV | 32 | 2 (6.3%) | 7 (21.9%) | 23 (71.9%) | |
| Recurrence | 0.004* | ||||
| No | 199 | 43 (21.6%) | 69 (34.7%) | 87 (43.7%) | |
| Yes | 37 | 3 (8.1%) | 7 (18.9%) | 27 (73.0%) | |
| Differentiation | 0.640 | ||||
| Well | 50 | 8 (16.0%) | 17 (34.0%) | 25 (50.0%) | |
| Moderate | 173 | 34 (19.7%) | 57 (32.92%) | 82 (47.4%) | |
| Poor | 13 | 4 (30.8%) | 2 (15.4%) | 7 (53.8%) | |
*Significant difference